---
title: 'INSPIRED Symposium Part 4B: CAR T cell correlative studies-established findings
  and future priorities'
date: '2023-10-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37863355/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231021180722&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'Chimeric antigen receptor (CAR) T cells have revolutionized the treatment
  of B cell malignancies, with multiple CAR T cell products having received approval
  by regulatory agencies around the world for numerous indications. However, significant
  work remains to be done to enhance these treatments. In March 2023, a group of experts
  in CAR T cell therapy assembled at the National Institutes of Health in Bethesda,
  MD, USA at the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances ...'
disable_comments: true
---
Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of B cell malignancies, with multiple CAR T cell products having received approval by regulatory agencies around the world for numerous indications. However, significant work remains to be done to enhance these treatments. In March 2023, a group of experts in CAR T cell therapy assembled at the National Institutes of Health in Bethesda, MD, USA at the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances ...